表紙
市場調查報告書
商品編碼
996618

多發性硬化症 (MS) 治療藥市場 - COVID-19影響與全球市場分析:至2027年的預測

Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Route of Administration, and Distribution Channel, and Geography

出版日期: | 出版商: The Insight Partners | 英文 169 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

多發性硬化症 (MS) 治療藥市場,從2019年的240億2,690萬美元,預計到2027年達到392億2,359萬美元,2020年∼2027年以6.5%的年複合成長率成長。

本報告提供全球多發性硬化症 (MS) 治療藥市場相關調查分析,市場形勢,市場動態,各分類市場分析,各地區市場分析,競爭情形,主要企業相關的系統性資訊。

目錄

第1章 簡介

第2章 多發性硬化症 (MS) 治療藥市場:要點

第3章 調查手法

第4章 全球多發性硬化症 (MS) 治療藥:市場形勢

  • 概要
  • PEST分析
  • 專家的見解

第5章 多發性硬化症 (MS) 治療藥市場:主要的市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 未來趨勢
  • 影響分析

第6章 多發性硬化症 (MS) 治療藥市場:全球分析

  • 全球多發性硬化症 (MS) 治療藥市場收益預測與分析
  • 全球多發性硬化症 (MS) 治療藥市場:各地區 - 預測與分析
  • 主要企業的市場定位

第7章 多發性硬化症 (MS) 治療藥市場分析:各藥物分類

  • 概要
  • 多發性硬化症 (MS) 治療藥市場收益佔有率:各藥物分類
  • 免疫抑制劑
  • 免疫調節劑

第8章 多發性硬化症 (MS) 治療藥市場分析:各給藥途徑

  • 概要
  • 多發性硬化症 (MS) 治療藥市場收益佔有率:各給藥途徑
  • 注射劑
  • 口服

第9章 多發性硬化症 (MS) 治療藥市場分析:各流通管道

  • 概要
  • 多發性硬化症 (MS) 治療藥市場佔有率:各流通管道
  • 醫院藥局
  • 零售藥局
  • 電子商務

第10章 多發性硬化症 (MS) 治療藥市場分析與預測:各地區分析

  • 北美:多發性硬化症 (MS) 治療藥市場
  • 歐洲:多發性硬化症 (MS) 治療藥市場
  • 亞太地區的多發性硬化症 (MS) 治療藥市場收益與預測
  • 中東、非洲的多發性硬化症 (MS) 治療藥市場收益與預測
  • 中南美:多發性硬化症 (MS) 治療藥市場

第11章 對全球多發性硬化症 (MS) 治療藥市場的COVID-19大流行的影響

  • 北美:COVID-19大流行的影響評估
  • 歐洲:COVID-19大流行的影響評估
  • 亞太地區:COVID-19大流行的影響評估
  • 中東、非洲:COVID-19大流行的影響評估
  • 中南美:COVID-19大流行的影響評估

第12章 產業形勢

  • 概要
  • 市場企業的成長策略
  • 有機的發展
  • 無機的發展

第13章 企業簡介

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD.
  • Biogen

第14章 附錄

目錄
Product Code: TIPRE00004057

The Multiple Sclerosis Therapeutics market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.

The growth of the multiple sclerosis therapeutics market is mainly attributed to factors, such as growing prevalence of multiple sclerosis (MS) and rise in funding for multiple sclerosis research. However, high cost of multiple sclerosis treatment is likely to restrain the market growth during the forecast period.

Multiple sclerosis is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS.

Rise in funding is fueling extensive multiple sclerosis research across the world to identify new treatments for the disease. For instance, Multiple Sclerosis Scientific Research Foundation announced the launch of 2017 Multi-Centre, Collaborative Team Grant (Team Grant) Competition. This grant would provide funding for multiple sclerosis research to the researchers and clinician scientists in Canadian institutions in association with other national and international experts. The research team can request up to US$ 4,500,000 for three years. Similarly, the National MS Society, in 2019, announced US$ 24.4 million funding for 64 new MS research projects. The society invested around US$ 35 million in 2019 alone to support 340 new and ongoing research studies across the globe. In 2018, the National MS Society Commits invested US$ 12 million for 40 new research projects in order to stop multiple sclerosis, restore function that has been lost due to the disease, and end multiple sclerosis forever.

COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID 19 has been established. Patients with severe health conditions, such as neurological diseases and others; are witnessing delays in such chronic disease treatment. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to open during the lock down. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the outbreak of COVID-19 pandemic.

Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in MS treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.

Based on route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and the same segment is anticipated to register higher CAGR during the forecast period.

Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.

The World Health Organization, Food and Drug Administration, Centers for Disease Control and Prevention, European Medicines Agency, National Center for Biotechnology Information, and National Health Service are some of the major primary and secondary sources referred for preparing this report.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Multiple Sclerosis Therapeutics market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global Multiple Sclerosis Therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Multiple Sclerosis Therapeutics Market - By Drug Class
    • 1.3.2 Global Multiple Sclerosis Therapeutics Market - By Route Of Administration
    • 1.3.3 Global Multiple Sclerosis Therapeutics Market - By Distribution Channel
    • 1.3.4 Global Multiple Sclerosis Therapeutics Market - By Geography

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Global Multiple Sclerosis Therapeutics- Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America - PEST Analysis
    • 4.2.2 Europe - PEST Analysis
    • 4.2.3 Asia Pacific - PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) - PEST Analysis
    • 4.2.5 South and Central America (SCAM) - PEST Analysis
  • 4.1 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
    • 5.1.2 Rising Funding for Multiple Sclerosis Research
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Multiple Sclerosis Treatment
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Awareness About Multiple Sclerosis
  • 5.4 Future Trends
    • 5.4.1 Development and Launch of Innovative Products
  • 5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - Global Analysis

  • 6.1 Global Multiple Sclerosis Therapeutics Market Revenue Forecast And Analysis
  • 6.2 Global Multiple Sclerosis Therapeutics Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class

  • 7.1 Overview
  • 7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
  • 7.3 Immunosuppressant
    • 7.3.1 Overview
    • 7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • 7.4 Immunomodulators
    • 7.4.1 Overview
    • 7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration

  • 8.1 Overview
  • 8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
  • 8.3 Injectable
    • 8.3.1 Overview
    • 8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • 8.4 Oral
    • 8.4.1 Overview
    • 8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel

  • 9.1 Overview
  • 9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
  • 9.3 Hospital Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.4 Retail Pharmacies
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • 9.5 E-Commerce
    • 9.5.1 Overview
    • 9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis And Forecast To 2027 - Geographical Analysis

  • 10.1 North America: Multiple Sclerosis Therapeutics Market
    • 10.1.1 Overview
    • 10.1.2 North America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
    • 10.1.3 North America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
    • 10.1.4 North America: Multiple Sclerosis Therapeutics Market, by Route of Administration, 2018-2027 (USD Million)
    • 10.1.5 North America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
    • 10.1.6 North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
    • 10.1.7 US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.1 US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.7.2 US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.1.7.3 US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.1.7.4 US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018-2027 (USD Million)
    • 10.1.8 Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.1 Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.8.2 Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.1.8.3 Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.1.8.4 Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018-2027 (USD Million)
    • 10.1.9 Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.1 Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.1.9.2 Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.1.9.3 Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.1.9.4 Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
  • 10.2 Europe: Multiple Sclerosis Therapeutics Market
    • 10.2.1 Overview
    • 10.2.2 Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
    • 10.2.3 Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
    • 10.2.4 Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
    • 10.2.5 Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.6 Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
    • 10.2.7 Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.1 Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.2 Germany Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.3 Germany Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.7.4 Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.8 UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.1 UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.2 UK Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.3 UK Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.8.4 UK Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
    • 10.2.9 France: Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.1 France: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.2 France Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.3 France Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.9.4 France Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.10 Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.1 Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.2 Spain Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.3 Spain Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.10.4 Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.11 Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.1 Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.2 Italy Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.3 Italy Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.11.4 Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
    • 10.2.12 Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.12.1 Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.2.12.2 Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
      • 10.2.12.3 Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
      • 10.2.12.4 Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • 10.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
    • 10.3.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
    • 10.3.4 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
    • 10.3.5 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
    • 10.3.6 Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
    • 10.3.7 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.7.1 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.7.2 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.3.7.3 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.3.7.4 China Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.3.8 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.8.1 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.8.2 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.3.8.3 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.3.8.4 Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.3.9 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.9.1 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.9.2 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.3.9.3 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.3.9.4 India Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.3.10 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.10.1 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.10.2 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.3.10.3 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
      • 10.3.10.4 South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.3.11 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.11.1 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.3.11.2 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.3.11.3 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.3.11.4 Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.3.12 Rest of Asia Pacific: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • 10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
    • 10.4.1 Overview
    • 10.4.2 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
    • 10.4.3 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
    • 10.4.4 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
    • 10.4.5 Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
    • 10.4.6 Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
    • 10.4.7 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.4.7.1 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.4.7.2 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.4.7.3 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.4.7.4 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
    • 10.4.8 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
      • 10.4.8.1 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.4.8.2 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.4.8.3 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.4.8.4 South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel US$ Mn)
    • 10.4.9 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
      • 10.4.9.1 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
      • 10.4.9.2 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
      • 10.4.9.3 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Route of Administration (US$ Mn)
      • 10.4.9.4 UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027, By Distribution Channel (US$ Mn)
      • 10.4.9.5 Rest of Middle East and Africa: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • 10.5 South and Central America: Multiple Sclerosis Therapeutics Market
    • 10.5.1 Overview
    • 10.5.2 South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
    • 10.5.3 South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
    • 10.5.4 South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
    • 10.5.5 South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
    • 10.5.6 South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
    • 10.5.7 Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.1 Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.7.2 Brazil: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.5.7.3 Brazil: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.5.7.4 Brazil: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
    • 10.5.8 Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.1 Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.8.2 Argentina: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.5.8.3 Argentina: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.5.8.4 Argentina: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)
    • 10.5.9 Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.1 Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
      • 10.5.9.2 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
      • 10.5.9.3 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
      • 10.5.9.4 Rest of South and Central America: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)

11. Impact of COVID-19 Pandemic on Global Multiple Sclerosis Therapeutics Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment Of COVID-19 Pandemic
  • 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
  • 11.5 South & Central America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Merck & Co., Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Bayer AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Sanofi
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Bristol-Myers Squibb Company
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Horizon Therapeutics plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Takeda Pharmaceutical Company Limited
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. HOFFMANN-LA ROCHE LTD.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Biogen
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 2. North America Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 3. North America Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 4. US Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 5. US Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 6. US Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
  • Table 7. Canada Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 8. Canada Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 9. Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
  • Table 10. Mexico Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 11. Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 12. Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 13. Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 14. Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 15. Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 16. Germany Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 17. Germany Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 18. Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 19. UK Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 20. UK Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 21. UK: Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million).
  • Table 22. France Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 23. France Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 24. France Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 25. Spain Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 26. Spain Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 27. Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 28. Italy Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 29. Italy Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 30. Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 31. Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 32. Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 33. Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 34. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 35. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 36. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 37. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 38. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 39. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 40. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 41. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 42. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 43. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 44. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 45. India Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 46. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 47. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 48. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 49. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 51. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 55. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 56. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 57. Middle East And Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 58. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 59. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 60. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 61. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 62. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 63. South Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 64. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Drug Class (US$ Mn)
  • Table 65. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
  • Table 66. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
  • Table 70. South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 71. South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 72. South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 73. Brazil Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 74. Brazil Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 75. Brazil Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 76. Argentina Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 77. Argentina Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 78. Argentina Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 79. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
  • Table 80. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
  • Table 81. Rest of South and Central America Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
  • Table 82. Organic Developments Done By Companies
  • Table 83. Inorganic Developments Done By Companies
  • Table 84. Glossary of Terms, Multiple sclerosis therapeutics Market

List Of Figures

  • Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
  • Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Region
  • Figure 3. Multiple Sclerosis Therapeutics Market Overview
  • Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share
  • Figure 5. APAC to Show Significant Growth During Forecast Period
  • Figure 6. Multiple Sclerosis Therapeutics Market, by Geography (US$ Million)
  • Figure 7. Global Multiple Sclerosis Therapeutics Market - Leading Country Markets (US$ Million)
  • Figure 8. Global Multiple Sclerosis Therapeutics Market, Industry Landscape
  • Figure 9. North America PEST Analysis
  • Figure 10. Europe PEST Analysis
  • Figure 11. Asia Pacific PEST Analysis
  • Figure 12. Middle East and Africa (MEA) PEST Analysis
  • Figure 13. South and Central America (SCAM) PEST Analysis
  • Figure 14. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
  • Figure 15. Global Multiple Sclerosis Therapeutics Market - Revenue Forecast And Analysis - 2019- 2027
  • Figure 16. Global Multiple Sclerosis Therapeutics Market - By Geography Forecast and Analysis - 2019- 2027
  • Figure 17. Market Positioning Of Key Players In Global Multiple Sclerosis Therapeutics Market
  • Figure 18. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
  • Figure 19. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 20. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 21. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
  • Figure 22. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 23. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 24. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
  • Figure 25. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 26. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 27. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
  • Figure 28. North America: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 29. North America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
  • Figure 30. North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
  • Figure 31. US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 32. Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 33. Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 34. Europe: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 35. Europe Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
  • Figure 36. Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
  • Figure 37. Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 38. UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 39. France: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 40. Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 41. Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 42. Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 43. Asia Pacific Multiple Sclerosis Therapeutics Market Overview, by Country (2019)
  • Figure 44. Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 45. Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
  • Figure 46. China Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 47. Japan Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 48. India Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 49. South Korea Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 50. Australia Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 52. Middle East & Africa Multiple Sclerosis Therapeutics Market Share Overview, By Country (2019)
  • Figure 53. Middle East And Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 54. Middle East And Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
  • Figure 55. Saudi Arabia Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 56. South Africa Multiple Sclerosis Therapeutic market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 57. UAE Multiple Sclerosis Therapeutics Market Revenue And Forecasts to 2027 (US$ Mn)
  • Figure 59. South and Central America: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
  • Figure 60. South and Central America Multiple Sclerosis Therapeutics Market Revenue and Forecast to 2027 (USD Million)
  • Figure 61. South and Central America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
  • Figure 62. Brazil: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 63. Argentina: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 64. Rest of South and Central America: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
  • Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
  • Figure 66. Impact of COVID-19 Pandemic in European Country Markets
  • Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
  • Figure 68. Impact of COVID-19 Pandemic in Middle East & Africa Market
  • Figure 69. Impact of COVID-19 Pandemic in South & Central America Market
  • Figure 70. Growth Strategies Done by the Companies in the Market, (%)